Ondine To Form Chronic Sinusitis Treatment Subsidiary

 
TIDMOBP 
 
Ondine To Form Chronic Sinusitis Treatment Subsidiary 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
June 29, 2010 
 
Ondine To Form Chronic Sinusitis Treatment Subsidiary 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 29, 2010) - Ondine Biopharma Corporation (the 
"Company" or "Ondine") (TSX:OBP)(AIM:OBP) a medical technology company developing photodisinfection 
based products, today announced its intention to establish a wholly owned subsidiary, "Sinuwave 
Technologies Corporation", dedicated to the development and commercialization of photodisinfection 
based products that address the chronic sinusitis market. The subsidiary will license all relevant 
Ondine intellectual property and know-how for this application, including technology internally 
developed over the past ten years and technology obtained in Ondine's December 2009 acquisition of 
Advanced Photodynamic Technologies Inc. ("APT"). Sinuwave Technologies will leverage the product 
development, clinical and regulatory experiences of both the Ondine and APT teams. 
 
"We believe the powerful antimicrobial and anti-inflammatory benefits of Ondine's photodisinfection 
technology have the potential to provide substantial relief to persons who suffer from chronic 
sinusitis," says Carolyn Cross, Chairman & CEO of Ondine Biopharma Corporation. "Over 43 million 
people in North America suffer from sinusitis. There are over 450,000 patients for whom sinus 
surgeries and antibiotics have been unsuccessful. We believe that we can apply our expertise as global 
leaders in photodisinfection to address this large unmet patient need." 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, 
fungal and viral infections. The Company is focused on developing leading edge products utilizing its 
patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy 
without encouraging the formation and spread of antibiotic resistance. The Company is based in 
Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, 
Washington, USA. 
 
For additional information, please visit www.ondinebiopharma.com and www.sinuwave.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", 
"expect" and other similar expressions, are forward-looking statements that involve a number of risks 
and uncertainties. Factors that could cause actual results to differ materially from those projected 
in the Company's forward-looking statements include the following: market acceptance of our 
technologies and products; our ability to obtain financing; our financial and technical resources 
relative to those of our competitors; our ability to keep up with rapid technological change; 
government regulation of our technologies; our ability to enforce our intellectual property rights and 
protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the 
timing of commercial product launches; the ability to achieve key technical milestones in key products 
and other risk factors identified from time to time in the Company's public filings. 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
[phone] 
[e-mail] 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Genuity Limited, Nominated Adviser 
Ryan Gaffney 
Nominated Adviser 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of 
this release. 
 
 
Ondine Biopharma Corporation